Achieve Life Sciences, Inc. (NASDAQ:ACHV) is set to announce third quarter earning results on Thursday 12th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, ACHV to report 3Q20 loss of $ 1.31 per share.
For the full year, analysts anticipate loss of $ 7 per share bottom line.
Stock Performance
Shares of Achieve Life Sciences, Inc. traded up $ 0.82 or 9.51 percent on Wednesday, reaching $ 9.44 with volume of 1.19 million shares. Achieve Life Sciences, Inc. has traded high as $ 10.38 and has cracked $ 8.56 on the downward trend
The closing price of $ 9.44, representing a 87.39 % increase from the 52 week low of $ 4.60 and a 69.21 % decrease over the 52 week high of $ 28.00.
The company has a market capital of $ 33.86 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 17th September 2020, initiated by Lake Street Capital at Buy rating, with $ 30.00 target price.
Conference Call
Achieve Life Sciences, Inc. will be hosting a conference call at 4:30 PM eastern time on 12th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, (877) 472-9809 U.S. or (629) 228-0791 Outside U.S., and the passcode is 8047128 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.achievelifesciences.com
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has a license agreement with Sopharma AD and University of Bristol.
